

EXHIBIT 415

IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF OHIO
EASTERN DIVISION

- - -

IN RE: NATIONAL : MDL NO. 2804
PRESCRIPTION OPIATE :
LITIGATION :
:

THIS DOCUMENT RELATES TO : CASE NO.
ALL CASES : 1:17-MD-2804
:
: Hon. Dan A.
: Polster

- - -

January 30, 2019

- - -

HIGHLY CONFIDENTIAL - SUBJECT TO FURTHER
CONFIDENTIALITY REVIEW

Videotaped deposition of JANET
GETZEY HART taken pursuant to notice, was held at
the law offices of Morgan, Lewis & Bockius LLP,
1701 Market Street, Philadelphia, Pennsylvania,
beginning at 9:34 a.m., on the above date, before
Ann Marie Mitchell, a Federally Approved
Certified Realtime Reporter, Registered Diplomat
Reporter, Registered Merit Reporter and Notary
Public.

- - -

GOLKOW LITIGATION SERVICES
877.370.3377 ph | 917.591.5672 fax
deps@golkow.com

<p style="text-align: right;">Page 114</p> <p>1 Q. Were any suspicious orders ever 2 reported to you at the corporate office? 3 A. There were none reported to me. 4 Q. And to be clear, you never 5 received a report of a suspicious order your 6 entire time working in the corporate office from 7 1995 through 2018. Correct? 8 A. I did not. 9 Q. Going down to paragraph 5, it 10 says, if a suspicious order is reported to 11 corporate, the corporate government affairs will 12 determine whether to "ship" or "do not ship." 13 Do you see that? 14 A. I do. 15 Q. And this is the same corporate 16 office that we just referred to, the government 17 affairs office. Right? 18 A. That is correct. 19 Q. So that would be you? 20 A. That would be me. 21 Q. How would you make the 22 determination of whether to ship or not ship? 23 A. There would be a number of 24 factors that would come into play. The very</p>	<p style="text-align: right;">Page 116</p> <p>1 factors based on? 2 A. Based on my knowledge of the 3 industry, based on my years of experience having 4 dealt with the DEA for a period of -- for a long 5 period of time, and knowing how to review a store 6 as far as its book of business, going way back to 7 even my days as the pharmacy district manager in 8 the Baltimore market. 9 Q. But to be clear, you never had to 10 make the decision whether to ship or not ship 11 because you never received any report of a 12 suspicious order. Right? 13 A. That is correct. 14 Q. And going down to paragraph 6, it 15 says, "All discussions, investigations and 16 reports will be maintained in the file designated 17 'Suspicious Orders.'" 18 Do you see that? 19 A. I do. 20 Q. Am I correct to assume that there 21 was no file designated suspicious orders because 22 there were no suspicious orders? 23 A. You are correct. 24 Q. Who would keep that file, if</p>
<p style="text-align: right;">Page 115</p> <p>1 first factor that I would look at is if it was an 2 auto ship order, that it came through the 3 algorithm and that was what the algorithm 4 provided. That would be a key one. 5 A second one would be to look at 6 the size of the order, to determine if the 7 unusual size of it was due to something at the 8 pharmacy that was placing the order, if there was 9 something unusual happening at that pharmacy. 10 Q. Anything else you would look at? 11 A. That would be it. 12 Q. Was there any written policy or 13 procedure about how to make that decision about 14 whether to ship or not ship? 15 A. To the best of my knowledge, no. 16 Q. So the factors you just testified 17 about that you would use to determine whether to 18 ship or not ship, those were just ones that you 19 yourself personally came up with. Right? 20 A. Yes. 21 MS. McENROE: Objection to form. 22 THE WITNESS: Sorry. 23 BY MR. POWERS: 24 Q. What were those based on, those</p>	<p style="text-align: right;">Page 117</p> <p>1 there was one? 2 A. Our office would maintain a file. 3 And there would be a file maintained at the 4 individual distribution center. 5 Q. How did you ensure that the 6 policy we just talked about in Exhibit 1 7 reflected on page 46179 was followed at the 8 distribution centers? 9 MS. McENROE: Objection to form. 10 THE WITNESS: The distribution 11 center has constant monitoring. They 12 have audits completed by our internal 13 audit group and by asset protection, and 14 by logistics and transportation, where 15 there are individual groups that go into 16 each of the distribution centers once a 17 year on behalf of Rite Aid and have a 18 checklist of compliance to review at the 19 distribution centers. 20 So there is a review done to make 21 sure that the processes are being 22 followed related to suspicious orders, 23 security. All of the policies and 24 procedures are reviewed and there is a</p>

1 threshold logs had already been shipped.
2 Correct?
3 A. Yes.

4 Q. I'm going to hand you what's been

5 marked as Rite Aid Exhibit Number -- or Rite
6 Aid_Hart Exhibit Number 6. It's a multi-page

7 document with the Bates number
8 Rite_Aid_OMDL_46227 through 46319. It's a pretty

9 long document. I'm just going to ask you
10 questions about the first page.

11 MS. McENROE: And, Will, do
12 you -- can you reference this is a
13 complete document?

14 MR. POWERS: I believe, once
15 again, it's the range that was identified
16 in the interrogatory responses.

17 - - -

18 (Deposition Exhibit No. Rite
19 Aid-Hart-6, Rite Aid Controlled Drug
20 Reporting Above Average Controlled Drug
21 Purchases Report, Bates stamped
22 Rite_Aid_OMDL_0046227 through
23 Rite_Aid_OMDL_0046319, was marked for
24 identification.)

1 - - -
2 THE WITNESS: (Reviewing
3 document.)

4 BY MR. POWERS: [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
 [REDACTED]
 [REDACTED]

☐ [Redacted]

☐ [REDACTED]

☐ [REDACTED]
☐ [REDACTED]
☐ [REDACTED]

☐ [Redacted]

☐ [REDACTED]
☐ [REDACTED]
☐ [REDACTED]
☐ [REDACTED]

■ [REDACTED]

☐ [REDACTED]
☐ [REDACTED]

